Anabel Elisa Rodriguez

Dr. Anabel Elisa Rodriguez

Instituto de Patobiologia Veterinaria (IPVET), INTA-CONICET
orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2012 in Infection, Genetics and Evolution
Verified
Journal Article
Closed access
Leonhard SchnittgerLeonhard Schnittger
Leonhard Schnittger
Anabel Elisa RodriguezAnabel Elisa Rodriguez
Anabel Elisa Rodriguez
Monica Florin-ChristensenMonica Florin-Christensen
Monica Florin-Christensen
DMDavid A. Morrison
David A. Morrison

28 July 2014 in Parasitology
Verified
Journal Article
Closed access
PDF file
Monica Florin-ChristensenMonica Florin-Christensen
Monica Florin-Christensen
CSCarlos E. Suarez
Carlos E. Suarez
Anabel Elisa RodriguezAnabel Elisa Rodriguez
Anabel Elisa Rodriguez
DFDaniela A. Flores
Daniela A. Flores
Leonhard SchnittgerLeonhard Schnittger
Leonhard Schnittger
SUMMARY: Bovine babesiosis caused by the tick-transmitted haemoprotozoansBabesia bovis, Babesia bigeminaandBabesia divergenscommonly results in substantial cattle morbidity and mortality in vast world areas. Although existing live vaccines confer protection, they have considerable disadvantages. Therefore, particularly in countries where large numbers of cattle are at risk, important research is directed towards improved vaccination strategies. Here a comprehensive overview of currently used live vaccines and of the status quo of experimental vaccine trials is presented. In addition, pertinent research fields potentially contributing to the development of novel non-live and/or live vaccines are discussed, including parasite antigens involved in host cell invasion and in pathogen-tick interactions, as well as the protective immunity against infection. The mining of available parasite genomes is continuously enlarging the array of potential vaccine candidates and, additionally, the recent development of a transfection tool forBabesiacan significantly contribute to vaccine design. However, the complication and high cost of vaccination trials hinderBabesiavaccine research, and have so far seriously limited the systematic examination of antigen candidates and prevented an in-depth testing of formulations using different immunomodulators and antigen delivery systems.

1 April 2014 in Ticks and Tick-borne Diseases
Verified
Journal Article
Closed access
Anabel Elisa RodriguezAnabel Elisa Rodriguez
Anabel Elisa Rodriguez
Monica Florin-ChristensenMonica Florin-Christensen
Monica Florin-Christensen
DFDaniela Agustina Flores
Daniela Agustina Flores
IEIgnacio Echaide
Ignacio Echaide
CSCarlos Esteban Suarez
Carlos Esteban Suarez
Leonhard SchnittgerLeonhard Schnittger
Leonhard Schnittger

15 December 2008 in Annals of the New York Academy of Sciences
Verified
Journal Article
Closed access
PDF file
LFLucas Ferreri
Lucas Ferreri
DBDaniel Benitez
Daniel Benitez
MDMariana Dominguez
Mariana Dominguez
Anabel Elisa RodriguezAnabel Elisa Rodriguez
Anabel Elisa Rodriguez
GAGustavo Asenzo
Gustavo Asenzo
Leonhard SchnittgerLeonhard Schnittger
Leonhard Schnittger

10 February 2010 in Veterinary Parasitology
Verified
Journal Article
Closed access
Anabel Elisa RodriguezAnabel Elisa Rodriguez
Anabel Elisa Rodriguez
ACAlicia Couto
Alicia Couto
IEIgnacio Echaide
Ignacio Echaide
Leonhard SchnittgerLeonhard Schnittger
Leonhard Schnittger
Monica Florin-ChristensenMonica Florin-Christensen
Monica Florin-Christensen

14 November 2016 in Parasites & Vectors
Verified
Journal Article
Open access
PDF file
AGAlba Marina Gimenez
Alba Marina Gimenez
KFKatia Sanches Françoso
Katia Sanches Françoso
JEJonatan Ersching
Jonatan Ersching
MIMarcelo Icimoto
Marcelo Icimoto
Vitor OliveiraVitor Oliveira
Vitor Oliveira
ISIrene Soares
Irene Soares
Babesia bovis is a tick-transmitted protozoan hemoparasite and the causative agent of bovine babesiosis, a potential risk to more than 500 million cattle worldwide. The vaccines currently available are based on attenuated parasites, which are difficult to produce, and are only recommended for use in bovines under one year of age. When used in older animals, these vaccines may cause life-threatening clinical symptoms and eventually death. The development of a multi-subunit recombinant vaccine against B. bovis would be attractive from an economic standpoint and, most importantly, could be recommended for animals of any age. In the present study, recombinant ectodomains of MSA-2a1, MSA-2b and MSA-2c antigens were expressed in Pichia pastoris yeast as secreted soluble peptides. The antigens were purified to homogeneity, and biochemically and immunologically characterized. A vaccine formulation was obtained by emulsifying a mixture of the three peptides with the adjuvant Montanide ISA 720, which elicited high IgG antibody titers against each of the above antigens. IgG antibodies generated against each MSA-antigen recognized merozoites and significantly inhibited the invasion of bovine erythrocytes. Cellular immune responses were also detected, which were characterized by splenic and lymph node CD4+ T cells producing IFN-γ and TNF-α upon stimulation with the antigens MSA-2a1 or MSA-2c. These data strongly suggest the high protective potential of the presented formulation, and we propose that it could be tested in vaccination trials of bovines challenged with B. bovis.